Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) EBITDA Margin: 2017-2025

Historic EBITDA Margin for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to -121.28%.

  • UroGen Pharma's EBITDA Margin fell 2841.00% to -121.28% in Q3 2025 from the same period last year, while for Sep 2025 it was -170.81%, marking a year-over-year decrease of 4211.00%. This contributed to the annual value of -140.30% for FY2024, which is 1683.00% down from last year.
  • UroGen Pharma's EBITDA Margin amounted to -121.28% in Q3 2025, which was up 41.20% from -206.27% recorded in Q2 2025.
  • UroGen Pharma's EBITDA Margin's 5-year high stood at -92.87% during Q3 2024, with a 5-year trough of -348.20% in Q1 2021.
  • For the 3-year period, UroGen Pharma's EBITDA Margin averaged around -147.31%, with its median value being -152.86% (2024).
  • In the last 5 years, UroGen Pharma's EBITDA Margin surged by 57,382bps in 2021 and then crashed by 5,341bps in 2025.
  • Quarterly analysis of 5 years shows UroGen Pharma's EBITDA Margin stood at -176.09% in 2021, then spiked by 1,679bps to -159.30% in 2022, then skyrocketed by 4,936bps to -109.94% in 2023, then crashed by 4,349bps to -153.44% in 2024, then tumbled by 2,841bps to -121.28% in 2025.
  • Its EBITDA Margin was -121.28% in Q3 2025, compared to -206.27% in Q2 2025 and -216.67% in Q1 2025.